Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors

<p>Glioblastoma patient characteristics (DFCI)</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Joseph Toker (15399882) (author)
Diğer Yazarlar:	J. Bryan Iorgulescu (15030477) (author), Alexander L. Ling (15399885) (author), Genaro R. Villa (15399888) (author), Josephina A.M.A. Gadet (15399891) (author), Laxmi Parida (15112564) (author), Gad Getz (14945542) (author), Catherine J. Wu (14944480) (author), David A. Reardon (15043854) (author), E. Antonio Chiocca (15399894) (author), Marco Mineo (15399897) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Cancer Detection and Diagnosis Immuno-oncology Biomarkers CNS Cancers Gliomas, Glioblastomas Immunotherapy Checkpoint blockade Skin Cancers Melanoma
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
Yazar:: Joseph Toker (15399882)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
Yazar:: Isha Mondal (16721699)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Yazar:: Francesca Orzan (15055579)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Yazar:: Francesca Orzan (15055579)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Yazar:: Francesca Orzan (15055579)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Yazar:: Michael Kilian (16697663)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Yazar:: Michael Kilian (16697663)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
Yazar:: Michael Kilian (16697663)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Yazar:: Sied Kebir (15048732)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Yazar:: Sied Kebir (15048732)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Yazar:: Sied Kebir (15048732)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Yazar:: Sied Kebir (15048732)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
Yazar:: Sied Kebir (15048732)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
Yazar:: Defne Bayik (14961098)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Yazar:: Qingsheng Xu (17078830)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
Yazar:: Qingsheng Xu (17078830)
Baskı/Yayın Bilgisi: (2025)

Graphical abstract from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
Yazar:: Reza Mirzaei (15306062)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S1 from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
Yazar:: Reza Mirzaei (15306062)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S2 from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
Yazar:: Reza Mirzaei (15306062)
Baskı/Yayın Bilgisi: (2025)

Figures 1 from Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
Yazar:: Bachchu Lal (17141949)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Yazar:: William Kelly (15439117)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Yazar:: William Kelly (15439117)
Baskı/Yayın Bilgisi: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Yazar:: Anne-Florence Blandin (15056366)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Yazar:: Tobias Kessler (17079209)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Yazar:: Tobias Kessler (17079209)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Yazar:: Tobias Kessler (17079209)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Yazar:: Tobias Kessler (17079209)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Yazar:: Tobias Kessler (17079209)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
Yazar:: Tobias Kessler (17079209)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_drvnpg474m9rg23do963akdjv8